Clinical Efficacy of Glucosamine Combined with Etoricoxib in the Treatment of Knee Osteoarthritis and Its Effects on Inflammatory Factors,Cartilage Metabolism and Matrix Metalloproteinases
Objective:To investigate the clinical efficacy of glucosamine combined with etoricoxib in the treatment of knee osteoarthritis(KOA)and its effects on inflammatory factors,cartilage metabolism and matrix metalloproteinases.Methods:A total of 106 KOA patients treated in a hospital from July 2020 to June 2023 were selected and assigned to the control group and observation group by random number table methed,with 53 patients in each group.The control group was treated with oral etoricoxib tablets,whereas the observation group was treated with glucosamine hydrochloride granules in addition to the treatment given in the control group,and both groups were treated for 4 weeks.The inflammatory factors[Toll-like receptor 4(TLR4),interleukin-1β(IL-1β)and tumor necrosis factor-ɑ(TNF-ɑ)],biomarkers of cartilage metabolism[cartilage oligomeric matrix protein(COMP),procollagen ⅡA of N-propeptide(PIIANP)and C-telopeptide of type Ⅱ collagen(CTX-Ⅱ],matrix metalloproteinases[matrix metalloproteinase-3(MMP-3),matrix metalloproteinase-9(MMP-9)],clinical efficacy and occurrence of adverse reactions were compared between the two groups.Results:After treatment,the levels of serum TLR4,IL-1β and TNF-ɑ were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The levels of serum COMP and CTX-Ⅱ were decreased in both groups(P<0.05),and were lower in the observation group than those in the control group(P<0.05).The level of serum PIIANP was increased in both groups(P<0.05),and was higher in the observation group than that in the control group(P<0.05).The levels of serum MMP-3 and MMP-9 were decreased in both groups(P<0.05),and was lower in the observation group than that in the control group(P<0.05).The total response rate in the observation group(94.34%)was higher than that in the control group(79.25%,P<0.05).There was no statistically significant difference in the incidence of treatment-emergent adverse reactions between the two groups(P>0.05).Conclusion:Glucosamine combined with etoricoxib has significant clinical efficacy in the treatment of KOA as demonstrated by effectively inhibited production of inflammatory factors and matrix metalloproteinases and improved cartilage metabolism biomarkers,without additional risks of adverse reactions.
万方数据
维普
